Scinai Immunotherapeutics Appoints Eilon Elmalem as Head of Yavne CDMO Facility

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne CDMO facility, effective June 14, 2026. Elmalem, who has supported the company as an external consultant for the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience and will oversee site operations and engineering activities as Scinai continues expanding its contract development and manufacturing platform.

The appointment is significant as it signals Scinai’s commitment to strengthening its CDMO capabilities, which are critical for the company’s growth strategy. The Yavne facility is a key asset for Scinai Biopharma Services, providing development and manufacturing services to biotechnology and pharmaceutical companies. By placing an experienced leader like Elmalem at the helm, the company aims to enhance operational efficiency and attract new clients.

Elmalem’s extensive background includes senior roles in biotech and pharma operations, where he has managed complex manufacturing processes and facility expansions. His previous work as an external consultant for Scinai has already provided him with deep insights into the company’s operations, ensuring a smooth transition. His responsibilities will include overseeing all site activities, from engineering to day-to-day operations, to ensure the facility meets regulatory standards and client expectations.

Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. Additionally, through its subsidiary Scinai Biopharma Services, it operates as a contract development and manufacturing organization (CDMO), offering services to other biotech and pharma firms. The expansion of the CDMO platform is part of Scinai’s broader strategy to generate revenue and support its internal pipeline.

The news was originally announced via a press release, which can be viewed at https://ibn.fm/VLt3w. For the latest news and updates relating to SCNI, the company’s newsroom is available at https://ibn.fm/SCNI.

This appointment comes at a time when the CDMO market is experiencing growth due to increasing demand for outsourced manufacturing services. By strengthening its leadership team, Scinai is positioning itself to capture a larger share of this market. The company’s focus on immunology therapies also aligns with broader industry trends, as the biopharmaceutical sector continues to invest in novel treatments for autoimmune and inflammatory diseases.